Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis.
Details
Serval ID
serval:BIB_F4AC47422194
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis.
Journal
BMC pulmonary medicine
ISSN
1471-2466 (Electronic)
ISSN-L
1471-2466
Publication state
Published
Issued date
09/05/2009
Peer-reviewed
Oui
Volume
9
Pages
18
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Publication Status: epublish
Abstract
The association between systemic sclerosis and pulmonary arterial hypertension (PAH) is well recognized. Vascular endothelial growth factor (VEGF) has been reported to play an important role in pulmonary hypertension. The aim of the present study was to examine the relationship between systolic pulmonary artery pressure, clinical and functional manifestations of the disease and serum VEGF levels in systemic sclerosis.
Serum VEGF levels were measured in 40 patients with systemic sclerosis and 13 control subjects. All patients underwent clinical examination, pulmonary function tests and echocardiography.
Serum VEGF levels were higher in systemic sclerosis patients with sPAP >or= 35 mmHg than in those with sPAP < 35 mmHg (352 (266, 462 pg/ml)) vs (240 (201, 275 pg/ml)) (p < 0.01), while they did not differ between systemic sclerosis patients with sPAP < 35 mmHg and controls. Serum VEGF levels correlated to systolic pulmonary artery pressure, to diffusing capacity for carbon monoxide and to MRC dyspnea score. In multiple linear regression analysis, serum VEGF levels, MRC dyspnea score, and D(LCO) were independent predictors of systolic pulmonary artery pressure.
Serum VEGF levels are increased in systemic sclerosis patients with sPAP >or= 35 mmHg. The correlation between VEGF levels and systolic pulmonary artery pressure may suggest a possible role of VEGF in the pathogenesis of PAH in systemic sclerosis.
Serum VEGF levels were measured in 40 patients with systemic sclerosis and 13 control subjects. All patients underwent clinical examination, pulmonary function tests and echocardiography.
Serum VEGF levels were higher in systemic sclerosis patients with sPAP >or= 35 mmHg than in those with sPAP < 35 mmHg (352 (266, 462 pg/ml)) vs (240 (201, 275 pg/ml)) (p < 0.01), while they did not differ between systemic sclerosis patients with sPAP < 35 mmHg and controls. Serum VEGF levels correlated to systolic pulmonary artery pressure, to diffusing capacity for carbon monoxide and to MRC dyspnea score. In multiple linear regression analysis, serum VEGF levels, MRC dyspnea score, and D(LCO) were independent predictors of systolic pulmonary artery pressure.
Serum VEGF levels are increased in systemic sclerosis patients with sPAP >or= 35 mmHg. The correlation between VEGF levels and systolic pulmonary artery pressure may suggest a possible role of VEGF in the pathogenesis of PAH in systemic sclerosis.
Keywords
Adult, Aged, Dyspnea/etiology, Dyspnea/metabolism, Female, Humans, Hypertension, Pulmonary/etiology, Hypertension, Pulmonary/metabolism, Linear Models, Lung/metabolism, Male, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Pulmonary Circulation, Respiratory Function Tests, Scleroderma, Systemic/complications, Scleroderma, Systemic/metabolism, Vascular Endothelial Growth Factor A/blood
Pubmed
Open Access
Yes
Create date
19/07/2019 19:42
Last modification date
20/08/2019 17:21
Usage data
